BioSpace News Archive

SeaSpine Holdings Corporation announced that it has commenced an underwritten public offering of shares of its common stock.

Amedisys, Inc. announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the J.P. Morgan 38th Annual Healthcare Conference in San Francisco, California on Tuesday, January 14, 2020.

Following the additional U.S. Food and Drug Administration clearance for its Cryoablation Technology, IceCure Medical Ltd., an Israeli medical device company, developers of a non-surgical Liquid Nitrogen cryoablation technology to destroy benign and cancerous tumors by freezing, plans to significantly extend its U.S. operations in target markets for indications with existing CPT codes and reimbursement.

Innovation announced several changes to the company’s leadership team.

Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced the appointment of Aoife Brennan, M.B., B.Ch., to its board of directors effective January 1, 2020.

The American Board of Medical Specialties (ABMS), the leading organization that oversees the standards for physician board certification in the United States, has named Greg Ogrinc, MD, MS its Senior Vice President, Certification Standards and Programs.

EncounterCare Solutions (ECSL) Pink Sheets. EncounterCare Solutions is pleased to announce that the OTC has recently published comments to SEC’s recent proposal to Rule 151-02 which governs public quoting of securities on OTC QX, OTC QB, and pink numbers.

Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, today announced the closing of a $4M financing.

Cagent Vascular, a developer of serration technology for vessel dilatation in cardiovascular disease interventions, announces the initiation of the PRELUDE-BTK Study

Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for spine fusion, trauma and osteoporosis markets, has announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.